Literature DB >> 16990775

Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia.

M Kreuter1, K Woelke, R Bieker, C Schliemann, M Steins, T Buechner, W E Berdel, R M Mesters.   

Abstract

Neuropilin-1 (NRP-1), a vascular endothelial growth factors and semaphorin receptor functioning as mediator of angiogenesis and neuronal guidance, is expressed by various solid tumors. The importance of NRP-1 in hematological malignancies such as acute myeloid leukemia (AML) remains to be elucidated. Therefore, we determined NRP-1 expression by immunohistochemical analysis of bone marrow biopsies of patients with newly diagnosed, untreated AML. The expression of NRP-1 was significantly increased in AML patients (n = 76; median 12.9 arbitrary units (a.u.)) as compared with controls (n = 38; median 2.75 a.u.). Survival was significantly poorer in patients with high (> median) versus low (< or = median) NRP-1 expression levels with 5-year overall survival rates of 16.9 versus 49.6% (P = 0.050). In conclusion, our data provide evidence of increased NRP-1 expression in AML with significant correlation to survival. Thus, NRP-1 might constitute a promising target for antileukemic and antiangiogenic treatment strategies in AML.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16990775     DOI: 10.1038/sj.leu.2404384

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  26 in total

1.  Neuropilin-1 is expressed by chronic lymphocytic leukemia B cells.

Authors:  Grzegorz S Nowakowski; Debabrata Mukhopadhyay; Xiaosheng Wu; Neil E Kay
Journal:  Leuk Res       Date:  2008-04-09       Impact factor: 3.156

Review 2.  Critical signal transduction pathways in CLL.

Authors:  Asish K Ghosh; Neil E Kay
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

3.  New markers for minimal residual disease detection in acute lymphoblastic leukemia.

Authors:  Elaine Coustan-Smith; Guangchun Song; Christopher Clark; Laura Key; Peixin Liu; Mohammad Mehrpooya; Patricia Stow; Xiaoping Su; Sheila Shurtleff; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Blood       Date:  2011-04-12       Impact factor: 22.113

4.  An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

Authors:  L Angenendt; S Reuter; D Kentrup; A S Benk; F Neumann; J Hüve; A C Martens; C Schwöppe; T Kessler; L H Schmidt; T Sauer; C Brand; J-H Mikesch; G Lenz; R M Mesters; C Müller-Tidow; W Hartmann; E Wardelmann; D Neri; W E Berdel; C Roesli; C Schliemann
Journal:  Leukemia       Date:  2017-06-30       Impact factor: 11.528

5.  Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2.

Authors:  Silvia Coma; Akio Shimizu; Michael Klagsbrun
Journal:  Cell Adh Migr       Date:  2011-05-01       Impact factor: 3.405

6.  Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia.

Authors:  Christopher J Walker; Krzysztof Mrózek; Hatice Gulcin Ozer; Deedra Nicolet; Jessica Kohlschmidt; Dimitrios Papaioannou; Luke K Genutis; Marius Bill; Bayard L Powell; Geoffrey L Uy; Jonathan E Kolitz; Andrew J Carroll; Richard M Stone; Ramiro Garzon; John C Byrd; Ann-Kathrin Eisfeld; Albert de la Chapelle; Clara D Bloomfield
Journal:  Blood Adv       Date:  2021-03-09

7.  Structural basis for ligand and heparin binding to neuropilin B domains.

Authors:  Craig W Vander Kooi; Manuel A Jusino; Benjamin Perman; David B Neau; Henry D Bellamy; Daniel J Leahy
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-03       Impact factor: 11.205

8.  Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding.

Authors:  Brent A Appleton; Ping Wu; Janice Maloney; JianPing Yin; Wei-Ching Liang; Scott Stawicki; Kyle Mortara; Krista K Bowman; J Michael Elliott; William Desmarais; J Fernando Bazan; Anil Bagri; Marc Tessier-Lavigne; Alexander W Koch; Yan Wu; Ryan J Watts; Christian Wiesmann
Journal:  EMBO J       Date:  2007-11-08       Impact factor: 11.598

9.  Integrative meta-analysis of differential gene expression in acute myeloid leukemia.

Authors:  Brady G Miller; John A Stamatoyannopoulos
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

10.  Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells.

Authors:  Emely Castro-Rivera; Sophia Ran; Rolf A Brekken; John D Minna
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.